Epigral Q2 Results FY27: PAT Jumps 24.8% to Rs 64.42 Cr, Revenue Rs 745.99 Cr

Epigral Ltd (EPIGRAL) Q2 Results FY27 announced on 2 November 2026, covering the company's financial performance for the July to September quarter. The results date brought standalone results with revenue of Rs 745.99 Cr and PAT of Rs 64.42 Cr, as filed with the NSE and BSE. Epigral Q2 Results FY27 therefore rest on a 27.01% rise in revenue and a 24.8% rise in net profit.

This Epigral Q2 Results review covers the financial highlights, the business drivers, the outlook and the risks, and the results analysis begins with the headline numbers in the Financial Highlights table that follows.

Click Here – Get Free Investment Predictions

Epigral Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 745.99 Cr	Rs 587.36 Cr	+27.01% YoY
Operating Profit	Rs 136.11 Cr	Rs 131.86 Cr	+3.22% YoY
Net Profit (PAT)	Rs 64.42 Cr	Rs 51.62 Cr	+24.8% YoY

Source: company filing for Epigral Q2 Results FY27, 2 November 2026. Figures in Rs Crore, Standalone basis.

Key Takeaways from Epigral Q2 Results: What Stands Out

• Revenue of Rs 745.99 Cr grew 27.01% YoY from Rs 587.36 Cr, the widest move among the three headline lines this quarter.
• Net profit of Rs 64.42 Cr rose 24.8% from Rs 51.62 Cr, so profit grew almost in step with revenue in Epigral Q2 Results FY27.
• Operating Profit of Rs 136.11 Cr edged up 3.22% from Rs 131.86 Cr, a slower YoY growth rate than revenue and net profit.
• Return ratios for FY26 were 16.09% on equity and 15.65% on capital employed, the latest full-year figures disclosed.
• Performance analysis follows next, comparing how the three lines moved against each other this quarter.

Epigral Q2 Results FY27: Performance Analysis

The performance analysis of Epigral Q2 Results FY27 shows that Epigral grew revenue to Rs 745.99 Cr in the July to September quarter, a gain of Rs 158.63 Cr over the Rs 587.36 Cr booked a year earlier. Net profit moved to Rs 64.42 Cr, up Rs 12.80 Cr, so the YoY growth in both lines was above 24%.

In this results analysis, Operating Profit rose from Rs 131.86 Cr to Rs 136.11 Cr, a gain of Rs 4.25 Cr or 3.22%. Revenue and net profit therefore grew far faster than Operating Profit, and the quarterly results on a standalone basis show the three lines moving in the same direction without matching in scale.

Epigral Q2 Results FY27 also give readers three items to follow in later disclosures. The first is whether revenue stays near the Rs 745.99 Cr level, and the second is whether net profit keeps pace with revenue. A third is how Operating Profit develops, and the Univest Screener can be used to compare these lines. Together, these checks lead into the business factors behind the Epigral Q2 Results.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The business factors start with revenue, which grew 27.01% year on year to Rs 745.99 Cr in the latest quarter, the first disclosed driver in Epigral Q2 Results FY27 and the largest single move among the reported lines.

Net Profit Growth – Net profit rose 24.8% year on year to Rs 64.42 Cr, and this quarterly results figure shows profit growth close to the pace of revenue growth during the quarter ended 30 September 2026.

Return Ratios – Return on equity was 16.09% in FY26 and return on capital employed was 15.65% in FY26, the two ratios disclosed for the full year, which sit alongside the profit growth reported for this quarter.

FY27 Outlook After Epigral Q2 Results

The FY27 full-year picture will depend on the quarters still to be reported and on disclosed sector conditions. Epigral Q2 Results FY27 set the second-quarter reference points of Rs 745.99 Cr in revenue and Rs 64.42 Cr in net profit, and the results analysis for later quarters can be measured against them.

Investors reading the results analysis can also watch whether YoY growth in revenue stays near the 27.01% recorded here and whether net profit holds near the Rs 64.42 Cr level. The next section covers the risks that the disclosed figures point to.

Key Risks to Watch After Epigral Q2 Results FY27

Volatile Quarterly Net Profit

Quarterly net profit has been volatile, ranging from Rs 39.11 Cr to Rs 99.18 Cr over the last 5 quarters, so the Rs 64.42 Cr in Epigral Q2 Results FY27 sits inside a wide range.

Sequential Fall in Net Profit

Net profit was down 35.0% quarter on quarter from Rs 99.18 Cr, which means the strong YoY growth of 24.8% sits alongside a lower figure than the one reported for the preceding quarter.

Lower Return on Equity

Return on equity declined to 16.09% in FY26 from 22.65% in FY25, a fall of 6.56 percentage points, and this ratio is worth watching in the annual filings that follow the quarterly results.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

The quarterly results from Epigral record standalone revenue of Rs 745.99 Cr and net profit of Rs 64.42 Cr, with Operating Profit at Rs 136.11 Cr. Epigral Q2 Results FY27 show growth in all three lines on a standalone basis, led by revenue. Univest readers should compare the Epigral Q2 Results figures with the filing and consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Epigral Q2 Results FY27

What are Epigral Q2 Results FY27?

Ans. Epigral Q2 Results FY27 are the standalone quarterly results for July to September 2026. Alongside this, they report revenue of Rs 745.99 Cr and net profit of Rs 64.42 Cr, as the Financial Highlights table shows.

What is the results date for Epigral Q2 Results FY27?

Ans. Epigral declared its Q2 FY27 results on 2 November 2026. This results date also marks the filing from which every figure in the Financial Highlights table and the article is taken.

What revenue was reported in Epigral Q2 Results FY27?

Ans. Epigral reported revenue of Rs 745.99 Cr in the quarter, compared with Rs 587.36 Cr a year earlier, so the Performance Analysis section records a rise of Rs 158.63 Cr.

What net profit was reported in Epigral Q2 Results FY27?

Ans. Epigral Q2 Results FY27 reported net profit of Rs 64.42 Cr. This compares with Rs 51.62 Cr a year earlier, which means the Key Takeaways section shows a rise of 24.8%.

How much YoY growth did revenue show in Epigral Q2 Results FY27?

Ans. Revenue showed YoY growth of 27.01% for Epigral in the quarter. Compared with the Rs 587.36 Cr base, the Rs 745.99 Cr figure is the largest move among the three lines in the Performance Analysis section.

Did net profit rise or fall in Epigral Q2 Results?

Ans. Epigral Q2 Results show net profit rose 24.8% YoY to Rs 64.42 Cr. Alongside this, the Key Risks section notes the figure was down 35.0% quarter on quarter from Rs 99.18 Cr.

What was the Operating Profit in Epigral Q2 Results FY27?

Ans. Epigral reported Operating Profit of Rs 136.11 Cr, against Rs 131.86 Cr a year earlier. This is a rise of 3.22%, so the Performance Analysis section shows it as the slowest-growing of the three lines.

Are Epigral Q2 Results consolidated results or standalone results?

Ans. Epigral Q2 Results are standalone results, covering the company on its own basis. Standalone results are the basis for every revenue, Operating Profit and net profit figure quoted in the Financial Highlights section.

What business factors shaped Epigral Q2 Results FY27?

Ans. The disclosed factors are 27.01% revenue growth, 24.8% net profit growth and FY26 return ratios of 16.09% on equity and 15.65% on capital employed. These are explained in the Key Business Factors section.

What are the key risks after Epigral Q2 Results FY27?

Ans. The disclosed risks are volatile quarterly net profit, a 35.0% quarter-on-quarter fall from Rs 99.18 Cr, and return on equity declining to 16.09% from 22.65%. Each is covered in the Key Risks section.

What is the outlook after Epigral Q2 Results?

Ans. The FY27 full-year picture depends on the quarters still to be reported. Meanwhile, the Outlook section treats Rs 745.99 Cr of revenue and Rs 64.42 Cr of net profit as the second-quarter reference points.

Where can I find the complete Epigral Q2 Results FY27 data?

Ans. The complete data is in the company's standalone filing on the NSE and BSE. Alongside this, the Univest app and this article summarise the key lines in the Financial Highlights table.